U.S. markets open in 3 hours 51 minutes

Marrone Bio Innovations, Inc. (MBII)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.50000.0000 (0.00%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close2.5000
Open2.5300
Bid1.4500 x 1400
Ask0.0000 x 3000
Day's Range2.4800 - 2.6300
52 Week Range0.6100 - 2.9000
Volume636,597
Avg. Volume606,978
Market Cap418.695M
Beta (5Y Monthly)0.08
PE Ratio (TTM)N/A
EPS (TTM)-0.1820
Earnings DateNov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Marrone Bio Innovations Stock Rose 12% Today
    Motley Fool

    Why Marrone Bio Innovations Stock Rose 12% Today

    The agricultural provider of sustainable bioprotection and plant health solutions said today it filed a $90 million shelf registration statement to potentially sell various securities over a three-year period. The proceeds would be used to give Marrone Bio more flexibility to finance future business opportunities, the company said in a statement. The company's biological solutions are used in the fast-growing sustainable agriculture segment to protect plants from diseases, insects, and weeds, promote plant health, and enhance water and nutrient efficiency.

  • Marrone Bio Innovations’ New Plant Health Product, Pacesetter®, Delivers a Six to One Return on Investment for Corn and Soybean Farmers
    GlobeNewswire

    Marrone Bio Innovations’ New Plant Health Product, Pacesetter®, Delivers a Six to One Return on Investment for Corn and Soybean Farmers

    Marrone Bio Expands into the 179 Million Acre Corn and Soybean MarketDAVIS, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations (MBI) (NASDAQ: MBII), announced today that its foliar plant health product for row crops, Pacesetter, showed outstanding performance in 2020 field trials in the U.S. Midwest. Grower demo trials saw an average of a six-to-one return on investment with improved yield of 6.4 bushels per acre in corn and 3.3 bushels per acre in soybeans. “Growers and distributors are very pleased with the results they saw from the Pacesetter field trials,” states Timothy Knight, senior director of North and Central American sales. “Using Pacesetter to produce healthier, higher-yielding plants, is an excellent example of how a BioUnite™ approach – combining biologicals and traditional chemistry – can help growers achieve the highest return for their crop.” Pacesetter is recommended for use with conventional fungicides to increase leaf chlorophyll content and improve plant health resulting in increased crop yield beyond what synthetic fungicides alone can generate. Developed for row crops such as corn, soybeans, cereal grains, cotton and more, Pacesetter has been shown to improve overall health and crop vigor, resulting in increased yields and profits. More than 90 field trials conducted throughout the Midwest during the 2020 growing season showed Pacesetter, when combined with a conventional fungicide, out-yielded fungicide use alone. Average return on investment in the trials was above six to one and numerous plant health benefits were witnessed. For corn, longer and wider ear leaf size, increased number of corn kernel rows, and longer and healthier corn kernels were observed. Soybeans had healthier plants and more pods per plant. In the past, MBI’s foliar products have been focused on specialty crops in the U.S. West and East Coast. With the introduction of Pacesetter, MBI is now able to reach the vast corn and soybean acreage of the Midwest – expected to be over 179 million acres in 2021, according to a November 10, 2020 USDA report. The introduction of the plant health product will provide growers with a novel solution to improve yield and return on investment. Pacesetter is currently available for sale in the U.S. and is approved for use on corn, soybeans, cereal grain, cotton and more. To learn more about Pacesetter, visit https://marronebio.com/products/pacesetter/. About Marrone Bio InnovationsMarrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection and plant health that help customers operate more sustainably while increasing their return on investment. MBI has screened over 18,000 microorganisms, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies and natural product chemistry to rapidly develop seven product lines. Supported by a robust portfolio of over 500 issued and pending patents, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven®, Pacesetter®, Zelto® Jet-Oxide® and Jet-Ag®, with a next-generation insecticide-nematicide, a breakthrough bioherbicide and a biofumigant in the Company’s product pipeline. MBI’s Pro Farm Finland-based subsidiary employs a proprietary technology derived from wood waste to stimulate plant growth and improve plant health, resulting in improved yields and crop quality. Products include UBP™ 110, Foramin®, UBP™ Seed Treatment, Foramin® ST. Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram. Marrone Bio Innovations Forward Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including, the sales potential in the U.S. Midwest, weather, the novel coronavirus COVID-19, regulatory and other factors affecting demand for the MBI’s products, any difficulty in marketing MBI’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise. Marrone Bio Innovations Contact:Clyde Montevirgen, VP of Business Development & Investor Relationsinfo@marronebio.com1-530-750-2800 Investor Relations Contact:Lucas A. ZimmermanSenior Vice PresidentMZ Group – MZ North AmericaMain: 949-259-4987MBII@mzgroup.us www.mzgroup.us

  • Marrone Bio Files $90 Million Shelf Registration Statement
    GlobeNewswire

    Marrone Bio Files $90 Million Shelf Registration Statement

    DAVIS, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in providing growers with sustainable bioprotection and plant health solutions to support global agricultural needs, announced today it has filed a “universal shelf” registration statement on Form S-3 with the Securities and Exchange Commission (SEC). Under the shelf registration, upon being declared effective by the SEC, Marrone Bio may offer and sell, from time to time over a three-year period, various securities in an amount of up to $90 million. The shelf registration statement is intended to afford Marrone Bio the flexibility to finance future business opportunities by accessing the capital markets on a timely and cost-effective basis. At the present time, the company has no specific plans to issue securities under the registration statement. The specifics of any future offering, along with the prices and terms of any such securities and the use of proceeds of a particular offering, will be determined at the time of any such offering and will be described in a prospectus supplement filed in connection with such offering. Marrone Bio Chief Executive Officer Kevin Helash noted, “Filing this registration statement is an important housekeeping step and a matter of standard corporate governance to allow us to pursue potential future growth initiatives and streamlines the process if circumstances arise that may require additional capital." The shelf registration statement relating to the securities has been filed with the SEC but has not yet become effective. The securities may not be sold, nor may offers to buy be accepted, prior to the time the shelf registration statement becomes effective under the Securities Act of 1933, as amended. Any offering of the securities will be made solely by means of a prospectus and an accompanying prospectus supplement relating to that offering. A copy of the preliminary prospectus included in the registration statement may be obtained on the SEC’s website at www.sec.gov. This press release is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Marrone Bio Innovations Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented agricultural company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, crop health and crop nutrition. Our portfolio of more than 15 products help customers operate more sustainably while increasing their return on investment. The company’s commercial products are sold globally and supported by a robust portfolio of over 400 issued and pending patents. Its agricultural end markets include row crops; fruits and vegetables; trees, nuts and vines; and greenhouse production. MBII’s research and development program uses proprietary technologies to isolate and screen naturally occurring microorganisms and plant extracts to create new, sustainable solutions in agriculture. Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram. Marrone Bio Innovations Forward Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing Marrone Bio’s views as of any subsequent date. Examples of such statements include statements regarding the potential effectiveness of the company’s shelf registration statement, the company’s ability to use the shelf registration statement access the capital markets and the company’s ability to use financing raised from the registration statement for future growth. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including the recent uncertainty in the global economy and industry-specific economy caused by the COVID-19 pandemic, consumer, regulatory and other factors affecting demand for the Company’s products, weather, regulatory and other factors affecting demand for the company’s products, any difficulty in marketing the company’s products in its target markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. Marrone Bio is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of current information, future events or otherwise. Company Contact: Clyde MontevirgenVice President of Business Development & Investor RelationsTelephone: 530-750-2800info@marronebio.com Investor Relations Lucas A. ZimmermanSenior Vice PresidentMZ Group – MZ North AmericaMain: 949-259-4987MBII@mzgroup.us